The IP commercialisation firm said it would hold a 33% stake in Insignals, which is a spin-out from the work of Professor João Paulo Cunha at the University of Porto and is developing wearable wireless devices to precisely measure wrist rigidity to help surgeons place brain implants more accurately during surgery on patients with Parkinson’s, epilepsy, and other neural conditions.
Wrist rigidity is used by doctors to decide the optimum position for an implant during surgery, but currently, this is done by two trained surgeons making a judgement by manually manipulating the wrist, meaning the procedure can be biased by the physicians' experience and perception.
Frontier said the device could help pharmaceutical companies monitor or assess the impact of new drugs in rigidity reduction during clinical trials, adding that Insignals had already received interest from potential industry partners and was looking to enter collaboration agreements to extend clinical trials in Portugal, the UK, and Germany.
Neil Crabb, Frontier’s chief executive, said that Insignals technology had “the potential to improve the accuracy of where to place an implant and relieve the symptoms of Parkinson's disease and other neural conditions”.
“The spin-out provides further evidence that we are now gaining serious traction in Portugal, a country with a lot of exciting IP and few companies providing commercialisation services."
João Paulo Cunha, co-founder of Insignals, added: "The creation of the Insignals Neurotech startup with our partners from Frontier IP will provide a strong innovation vehicle to consolidate the neuro-technology we've been developing for several years."
In early trading Tuesday, Frontier IP shares were up 0.6% at 87p.
--Adds share price--